Elsevier

Vaccine

Volume 28, Issue 16, 1 April 2010, Pages 2799-2800
Vaccine

Improving the public health: The U.S. recommendation for universal influenza immunization

https://doi.org/10.1016/j.vaccine.2010.03.002Get rights and content

Section snippets

Disclosures

Dr. Poland serves as the chair of a safety evaluation committee for a novel influenza vaccine being developed my Merck Research Laboratories. He has provided consultative advice on novel influenza vaccine development to Avianax LLC, Theraclone Sciences, MedImmune LLC, Liquidia Technologies, Inc., Novavax, and PAXVAX, Inc.

Dr. Morse was a member of the CDC's ACIP from 2005 to 2009 and Chair from 2007 to 2009.

References (2)

Cited by (11)

  • Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity

    2020, Vaccine
    Citation Excerpt :

    Mass vaccination is one of the most effective means of combating the influenza. It has been estimated that universal influenza vaccination can save the lives of between 250,000 and 500,000 people every year worldwide [1]. Russian Federation National Immunization Schedule approves the use of several vaccines, including vaccines of the Grippol family, for mass immunization against influenza in Russia.

  • Attitudes of dental healthcare workers towards the influenza vaccination

    2012, International Journal of Hygiene and Environmental Health
    Citation Excerpt :

    Influenza viruses are highly infectious and cause annual epidemics and periodic pandemics. The most important prevention strategy is the annual immunization (Poland and Morse, 2010; Rueckmann et al., 2009). Influenza immunization has long been recommended for healthcare workers (HCWs).

  • Inactivated and adjuvanted influenza vaccines

    2015, Current Topics in Microbiology and Immunology
View all citing articles on Scopus
View full text